Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: A multicentre randomised trial

Lancet

Volumn 359, Issue 9317, 2002, Pages 1555-1563

  Maughan, T S ^a   James, R D ^b   Kerr, D J ^c   Ledermann, J A ^d   McArdle, C ^e   Seymour, M T ^f   Cohen, D ^g   Hopwood, P ^h   Johnston, C ⁱ   Stephens, R J ⁱ  

^a VELINDRE CANCER CENTRE   (United Kingdom)

^b MAIDSTONE HOSPITAL   (United Kingdom)

^c RADCLIFFE INFIRMARY   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^e GLASGOW ROYAL INFIRMARY   (United Kingdom)

^f Northern and Yorkshire Clinical Trials and Research Unit   (United Kingdom)

^g UNIVERSITY OF GLAMORGAN   (United Kingdom)

^h CHRISTIE HOSPITAL   (United Kingdom)

ⁱ MRC CLINICAL TRIALS UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FLUOROURACIL DERIVATIVE; FOLINIC ACID PLUS FLUOROURACIL; RALTITREXED; UNCLASSIFIED DRUG; WARFARIN;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HUMAN; LETHARGY; LEUKOPENIA; MALE; METASTASIS; MULTICENTER STUDY; NEUTROPENIA; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RASH; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0037018765     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)08514-8     Document Type: Article

References (37)

1. Estimates of the worldwide incidence of 25 major cancers in 1990
2. Recurrent and advanced disease
3. Palliative chemotherapy for advanced colorectal cancer: Systematic review and meta-analysis
4. Fluorinated pyrimidines: A new class of tumour inhibitory compounds
5. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate
6. Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer
7. Mini-meta-analysis of toxicity of full dose Mayo regimen (FUFA) from two randomized controlled trials (RCTs): A concern about dose (abstr)
8. High-dose leucovorin and 5-fluorouracil bolus and infusion in advanced colorectal cancer
9. Randomised trial comparing monthly low dose leucovorin and fluorouracil bolus with bimonthly high dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer
10. A prospective randomised comparison of continuous infusion flourouracil with a conventional bolus schedule in metastatic colorectal carcinoma
11. Efficacy of intravenous continuous infusion of 5-fluorouracil compared with bolus administration in advanced colorectal cancer
12. Toxicity of fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors
13. ICI D 1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumour cell growth in vitro and in vivo: A new agent for clinical study
14. Phase 1 study of the new thymidylate synthase inhibitor 'Tomudex' (ZD 1694) in advanced malignancy (abstr)
15. Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer
16. Raltitrexed (Tomudex) versus 5-fluorouracil and leucovorin (5-FU + LV) in patients with advanced colorectal cancer (ACC): Results of a randomized, multicenter, North American trial (abstr)
17. Open, randomized multicenter trial of raltitrexed versus fluorouracil plus high dose leucovorin in patients with advanced colorectal cancer
18. Overview of the tolerability of 'Tomudex' (raltitrexed): Collective clinical experience in advanced colorectal cancer
19. The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality of life instrument for use in international clinical trials in oncology
20. The Hospital Anxiety and Depression Scale
21. Randomised trial assessing the addition of interferon α-2a to fluorouracil and leucovorin in advanced colorectal cancer
22. Evaluation of active control trials in AIDS
23. Approaches to the analysis of quality of life data: Experiences gained from a Medical Research Council Lung Cancer Working Party palliative chemotherapy trial
24. Defining and analysing symptom palliation in cancer clinical trials: A deceptively difficult exercise
25. Survival impact of chemotherapy in patients with colorectal metastases confined to the liver: A meta-analysis of 1,458 non-operable patients randomized in 22 trials (abstr)
26. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
27. Impact of second and third line FU-based chemotherapy on the survival of patients with advanced colorectal cancer
28. Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex ZD1694)
29. Folate depletion is associated with significant haematological toxicity in patients treated with raltitrexed (Tomudex) for colorectal cancer (abstr)
30. Phase I trial of ZD1694 ('Tomudex') a direct inhibitor of thymidylate synthase (abstr 241)
31. Leucovorin rescue from raltitrexed (Tomudex)-induced antiproliferative effects: In vitro call line and in vivo mouse studies
32. Randomized trials with quality of life endpoints: Are doctors' ratings of patients' physical symptoms interchangeable with patients' self-ratings?
33. Dose-escalation study of a modified 'de Gramont' regimen, better suited to the chemotherapy day unit
34. Oxaliplatin with high-dose leucovorin and 5FU 48-hour continuous infusion in pretreated metastatic colorectal cancer